Summary:
- Cerevance is a biotechnology company focused on developing new treatments for neurological and psychiatric disorders.
- The article interviews Craig Thompson, the CEO of Cerevance, who discusses the company's approach to drug discovery and their efforts to address unmet needs in the field of neuroscience.
- Cerevance is utilizing a unique platform technology to identify novel drug targets and develop potential therapies for conditions such as Alzheimer's disease, Parkinson's disease, and depression.